certaines preuves etablissent un lien formel entre des taux de HDL-CHOLESTEROL bas et un erotic cardiovasculaire plus grand. Ce qui justifie le ciblage du Hdl-cholesterol dans la prevention et le purchase Dalcetrapib traitement des maladies cardiovasculaires. Les approches therapeutiques en ce sens incluent des perfusions directes de HDL cholesterol et dagents HDL mimetiques, de meme que linhibition de la proteine de transfert des esters de cholesterol. Linhibition delaware manhattan project CETP semble une strategie particulierement prometteuse. Le torcetrapib, un inhibiteur de manhattan project CETP, fait effectivement augmenter de 40 a 60-100, les taux plasmatiques de HDL cholesterol tout durante reduisant de maniere modeste le LDL cholesterol. En alliant un inhibiteur de la CETP, fill ses proprietes qui agissent a la hausse sur le HDL cholesterol, et une statine, qui agit a la baisse sur le LDL cholesterol, les resultats pourraient etre plus satisfaisants quen ne ciblant que le LDL cholesterol. Cette hypothese fait lobjet Skin infection detudes exhaustives dans le cadre dun plan complet qui comprend notamment des examens dimagerie et un essai de grande envergure reposant sur des parametres cliniques. La defense cardiovasculaire additionnelle requise chez les patients atherosclereux ou presentant des facteurs de risque equivalents pourrait bien provenir de traitements qui agissent au-dela de la simple decline du LDL D. Raised low density lipoprotein cholesterol is a powerful independent risk factor for cardiovascular disease. Several studies have shown that statins have allowed us to enter the period of atherosclerosis regression. Indeed, 12 months of treatment with simvastatin is proven to cause a paid off coronary atheroma size, as assessed by intravascular ultrasound. Equally, savings in total atheroma Lapatinib 388082-77-7 size on intravascular ultrasound were seen in the placebo arms of other intravascular ultrasound studies, like the Avasimibe and Progression of Lesions on UltraSound and acyl coenzyme A:cholesterol acyltransferase IntraVascular Atherosclerosis Treatment Evaluation trials, when the great majority of people were treated with statins. More over, regression of atherosclerosis was observed in both statin arms of the Reversing Atherosclerosis with Aggressive Lipid lowering research when determining the subsegment with the largest illness burden, and the result was significantly more marked in the more intensive lipid lowering arm with 80 mg of atorvastatin. Now, regression of atherosclerosis was also noticed with 40 mg of rosuvastatin in Research To Judge the result of Rosuvastatin On Intravascular ultrasound Derived coronary atheroma pressure. However, the reduced amount of cardiovascular events by approximately one third with statins have not only illustrated their efficacy but additionally the unmet medical need. Ergo, a large number of atherosclerosis related clinical events are not being prevented with current pharmacological approaches.